Emmessar Biotech & Nutrition Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Emmessar Biotech & Nutrition şirketinin toplam hissedar öz sermayesi ₹77.7M ve toplam borcu ₹0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹92.9M ve ₹15.2M dir. Emmessar Biotech & Nutrition 'in FAVÖK'ü ₹4.4M faiz karşılama oranı -0.9 dur. Şirketin ₹66.5M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

₹0

Borç

Faiz karşılama oranı	-0.9x
Nakit	₹66.54m
Eşitlik	₹77.70m
Toplam yükümlülükler	₹15.15m
Toplam varlıklar	₹92.85m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 524768 'nin kısa vadeli varlıkları ( ₹74.2M ) kısa vadeli yükümlülüklerini ( ₹5.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 524768 şirketinin kısa vadeli varlıkları ( ₹74.2M ) uzun vadeli yükümlülüklerini ( ₹9.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 524768 borçsuzdur.

Borcun Azaltılması: 524768 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 524768 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 524768 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Emmessar Biotech & Nutrition Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.56 (vs ₹0.39 in 2Q 2024)

Investor sentiment improves as stock rises 27%

Emmessar Biotech & Nutrition Limited to Report Q2, 2025 Results on Nov 07, 2024

Investor sentiment improves as stock rises 20%

Emmessar Biotech & Nutrition Limited Announces Change in Directorate

First quarter 2025 earnings released: EPS: ₹0.18 (vs ₹0.11 in 1Q 2024)

Emmessar Biotech & Nutrition Limited, Annual General Meeting, Sep 27, 2024

Emmessar Biotech & Nutrition Limited to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Full year 2024 earnings released: EPS: ₹1.48 (vs ₹1.01 in FY 2023)

Emmessar Biotech & Nutrition Limited to Report Fiscal Year 2024 Results on May 29, 2024

Investor sentiment improves as stock rises 18%

Emmessar Biotech & Nutrition Limited Approves Appointment of Dinesh Kumar Deora as an Additional Independent Director (Non- Executive)

Investor sentiment deteriorates as stock falls 17%

Third quarter 2024 earnings released: EPS: ₹0.26 (vs ₹0.04 loss in 3Q 2023)

Investor sentiment improves as stock rises 20%

Emmessar Biotech & Nutrition Limited to Report Q3, 2024 Results on Feb 03, 2024

Second quarter 2024 earnings released: EPS: ₹0.39 (vs ₹0.27 in 2Q 2023)

Emmessar Biotech & Nutrition Limited to Report Q2, 2024 Results on Dec 09, 2023

New minor risk - Profit margin trend

Full year 2023 earnings released: EPS: ₹0.99 (vs ₹0.94 in FY 2022)

Emmessar Biotech & Nutrition Limited Approves the Appointment of Srinivasa Raghavan Mathurakavi Ayyangar as Chairman

Emmessar Biotech & Nutrition Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Financial data availability

Emmessar Biotech & Nutrition Limited to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Share price stability

Emmessar Biotech & Nutrition Limited to Report Q3, 2023 Results on Feb 04, 2023

Emmessar Biotech & Nutrition Limited Announces Resignation of Vijaykumar Raghunandan Prasad from Board of Directors

Investor sentiment improved over the past week

Less than half of directors are independent

Emmessar Biotech & Nutrition Limited Approves Appointment of Milind Sitaram Desai as Additional Independent Director

Emmessar Biotech & Nutrition Limited to Report First Half, 2023 Results on Oct 20, 2022

Emmessar Biotech & Nutrition Limited Announces Resignation of Director

Full year 2022 earnings released: EPS: ₹0.94 (vs ₹2.90 in FY 2021)

Investor sentiment improved over the past week

Emmessar Biotech & Nutrition Limited to Report Q1, 2023 Results on Aug 08, 2022

Emmessar Biotech & Nutrition Limited, Annual General Meeting, Aug 08, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Emmessar Biotech & Nutrition Limited to Report Q3, 2022 Results on Feb 11, 2022

Second quarter 2022 earnings released: EPS ₹0.37 (vs ₹0.91 in 2Q 2021)

First quarter 2022 earnings released: EPS ₹0.18 (vs ₹0.06 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹2.88 (vs ₹1.51 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹15.80

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹0.90 (vs ₹0.48 in 3Q 2020)

Emmessar Biotech & Nutrition Limited Appoints Jeyavel Balaiah Nadar as Executive Director

Emmessar Biotech & Nutrition Limited to Report Q3, 2021 Results on Feb 06, 2021

Market bids up stock over the past week

Emmessar Biotech & Nutrition Limited Appoints Anantharama Sethumani Subramanian as Additional Independent Director with Effect from November 6, 2020

Market bids up stock over the past week

New 90-day high: ₹17.73

Full year earnings released - EPS ₹1.51

New 90-day high - ₹14.70

Emmessar Biotech & Nutrition Limited to Report Q4, 2020 Results on Jun 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin